Study on the Clinical Efficacy of Transcranial Strong Alternating Current (Hi-tACS) in Patients With Neuroimmune Diseases With Insomnia
A legfontosabb adatok
- Ki végzi
- Xuanwu Hospital, Beijing
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 80 fő, tervezett
- Kezdés
- 2025. szept. 1.
- Várható befejezés
- 2027. júl. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- high-intensity transcranial alternating current stimulation, hi-tACS
- Sham hi-tACS
- A regiszteradat frissítve
- 2026. április 30.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with insomnia. Some have a nerve-immune disease (NMOSD or multiple sclerosis), others have chronic primary insomnia only.
- Életkor
- 18 to 65 years
- Nem
- All sexes. Women aged 18-50 must agree to use birth control during the study.
- A betegség stádiuma
- Insomnia on at least 3 nights per week for more than 3 months, with severe daytime problems (Pittsburgh Sleep Quality Index item 7 score ≥2). People with NMOSD or MS must meet the diagnostic criteria.
- Korábbi kezelés
- No sleeping pills or insomnia medicine for at least 4 months. No medicine change, electroconvulsive therapy, transcranial magnetic stimulation or similar brain stimulation in the past 1 month. People must agree to have no other treatments during the study.
A részvétel fő kizáró okai
- A disease relapse in the past 1 month
- Cochlear implant, heart pacemaker or implanted brain stimulator
- Brain diseases such as epilepsy, hydrocephalus, brain tumor, head injury or brain infection
- Pregnant or breastfeeding, or planning pregnancy soon
- Suicide risk, severe mental disorder, other sleep disorders, or night shift work
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- Patients with idiopathic inflammatory demyelinating disorders (IIDDs) meeting the diagnostic criteria, including neuromyelitis optica spectrum disorders (NMOSD) [based on the Chinese Guidelines for Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (2016 Edition)] and multiple sclerosis (MS) [based on the Chinese Guidelines for Diagnosis and Treatment of Multiple Sclerosis (2023 Edition)], and accompanied by insomnia; Aged between 18 and 65 years, regardless of gender; Experiencing difficulty falling asleep, difficulty maintaining sleep, or early morning awakening on at least 3 nights per week for more than 3 months; Severe daytime functional impairment (Chinese version of the Pittsburgh Sleep Quality Index, item 7 [daytime dysfunction] ≥2); Having not taken hypnotics or insomnia treatment medication for at least 4 months; Female participants aged 18-50 years who agree to use effective contraception throughout the study period; Agreeing to refrain from receiving medication or other non-pharmacological treatments during the study period; Agree to participate and sign the informed consent
- Patients diagnosed with chronic primary insomnia according to 《The Diagnostic and Statistical Manual of Mental Disorders》(Text Revision) (DSM-IV-TR) or 《International Classification of Diseases Tenth Revision》(ICD-10):; Aged between 18 and 65 years, regardless of gender; Experiencing difficulty falling asleep, difficulty maintaining sleep, or early morning awakening on at least 3 nights per week for more than 3 months; Severe daytime functional impairment (Chinese version of the Pittsburgh Sleep Quality Index, item 7 [daytime dysfunction] ≥2); Having not taken hypnotics or insomnia treatment medication for at least 4 months; Female aged 18~50 years agreeing to adopt birth control measures during the study period; Agreeing to refrain from receiving medication or other non-pharmacological treatments during the study period; Agree to participate and sign the informed consent
Ki nem vehet részt
- Drug adjustment within the past 1 month, or receipt of modified electroconvulsive therapy, transcranial magnetic stimulation therapy, or other neuralcontroltechnology therapy
- Participation in any other clinical studies within 1 month prior to enrollment or currently
- History of relapse within the past 1 month
- Presence of cochlear implant system, cardiac-pacemaker, or intracerebral implanted stimulators
- Impaired skin integrity at the electrode placement site, or allergy to electrode gel or adhesive
- History of organic brain diseases such as epilepsy, hydrocephalus, tumor of central nervous system, craniocerebral injury, or intracranial infection
- A score of ≥3 on the suicide item of the Hamilton Depression Scale, or coexisting severe mental disorders
- Presence of severe or unstable organic diseases
- Presence of other sleep disorders
- Pregnant or lactating women, or those intending pregnancy soon
- Work night shifts
- Poor patient compliance preventing cooperation with treatment, follow-up, or clinical, electroencephalographic (EEG), or imaging data collection
- Other circumstances deemed by the investigator as inappropriate for study participation
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 65 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study aims to comprehensively evaluate the therapeutic effects of high-intensity transcranial alternating current stimulation (hi-tACS) on insomnia symptoms in patients with idiopathic inflammatory demyelinating disorders (IIDDs) by analyzing both the overall disease characteristics of IIDDs and individual patient variability. Additionally, the study will investigate the neuroimmunomodulatory mechanisms of hi-tACS. The findings are expected to provide evidence for the clinical application of hi-tACS in managing insomnia in IIDDs and offer new insights for personalized treatment strategies.
A vizsgálat 2 csoportja
- Neuromodulation GroupA vizsgált kezelés
Participants receive active transcranial alternating current stimulation (tACS) using the Nexalin ADI device. Electrodes are placed on the forehead (Fp1, Fpz, Fp2 areas of the international 10-20 system; electrode size 4.45 cm × 9.53 cm) and on bilateral mastoids (two electrodes, each 3.18 cm × 3.81 cm). Each session lasts 40 minutes, once daily, for 4 consecutive weeks (5 days intervention + 2 days rest, total 20 sessions). After completing the 20 sessions, there is a 4-week follow-up period without any treatment. At the end of week 4 and at 1 month and 2 months post-treatment, participants are asked about discomfort, abnormal sensations, seizure occurrence, and treatment acceptability.
Kezelés: high-intensity transcranial alternating current stimulation, hi-tACS
- Sham Neuromodulation GroupPlacebo, összehasonlításként
Participants receive sham stimulation using a device identical in appearance, buttons, electrodes, odor, and weight to the active device, but no current is delivered. Both participants and investigators are blinded to group assignment. The sham device produces an initial similar sensation to real stimulation to maintain blinding. The treatment schedule (once daily, 40 minutes per session, 20 sessions over 4 weeks) and follow-up assessments are identical to those in the active group.
Kezelés: Sham hi-tACS
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07558616: ki vehet részt
- A regiszteradat frissítve
- 2026. április 30.